Physician specialty
Hematology & Oncology
At a glance
- Practicing in the U.S.
- 13,608
- Per 100,000 residents
- 4.0
- Women
- 36%
- Median years since graduating
- 22
Training path
- College (bachelor’s degree) 4 years
- Medical school (MD or DO) 4 years
- Internal medicine residency 3 years
- Hematology and medical oncology fellowship 3 years
Training after medical school: 6 years. From the start of college: about 14 years.
Usual minimum program lengths from ACGME program requirements. Some doctors take extra research years or a second fellowship.
Who they are
- MD (DOs make up the rest) 95%
- Women 36%
- Graduated 35 or more years ago 22%
- Offer telehealth 58%
- Accept Medicare’s approved amount 97%
Sex and credentials from NPPES. Graduation year, telehealth and Medicare assignment from Medicare Care Compare, which covers clinicians enrolled in Medicare.
Where they practice
What they do most for Medicare patients
- Established patient office or other outpatient visit, 30-39 minutes 2,985,577
- Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 2,261,618
- Insertion of needle into vein for collection of blood sample 1,944,424
- Blood test, comprehensive group of blood chemicals 1,201,440
- Established patient office or other outpatient visit, 20-29 minutes 1,187,591
- Established patient office or other outpatient visit, 40-54 minutes 1,117,544
- Administration of chemotherapy into vein, 1 hour or less 716,225
- Injection of drug or substance under skin or into muscle 714,845
- Injection of additional new drug or substance into vein 692,512
- Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 566,659
- Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes 435,439
- Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes 414,786
Services billed to traditional Medicare in 2023 (Physician and Other Practitioners data); drugs given in the office are left out.
What they prescribe most
- Anastrozole (Arimidex) 9.3%
- Apixaban (Eliquis) 5.2%
- Letrozole (Femara) 4.7%
- Prednisone (Rayos) 4.3%
- Dexamethasone (Hemady, Maxidex, Ozurdex) 3.3%
- Hydroxyurea (Siklos, Droxia, Hydrea) 3.1%
- Acyclovir (Zovirax) 3.0%
- Lenalidomide (Revlimid) 3.0%
- Ondansetron Hcl 2.9%
- Prochlorperazine Maleate 2.8%
- Abiraterone Acetate (Zytiga) 2.3%
- Gabapentin (Gralise, Neurontin) 2.3%
- Tamoxifen Citrate (Soltamox) 2.1%
- Oxycodone Hcl (Oxycontin, Roxicodone, Roxybond) 1.9%
- Hydrocodone/Acetaminophen (Hydrocodone-Acetaminophen) 1.9%
Share of this specialty’s Medicare Part D prescriptions in 2024, including refills. Select a drug to see which of these clinicians prescribe it most, and where.
Hospitals where the most work
- Brigham and Women's Hospital Boston, MA 122 Hematology & Oncology at Brigham and Women's Hospital
- Hospital of Univ of Pennsylvania Philadelphia, PA 119 Hematology & Oncology at Hospital of Univ of Pennsylvania
- Cleveland Clinic Cleveland, OH 100 Hematology & Oncology at Cleveland Clinic
- Northside Hospital Atlanta, GA 96 Hematology & Oncology at Northside Hospital
- Northwestern Medicine Central Dupage Hospital Winfield, IL 93 Hematology & Oncology at Northwestern Medicine Central Dupage Hospital
- Ronald Reagan UCLA Medical Center Los Angeles, CA 91 Hematology & Oncology at Ronald Reagan UCLA Medical Center
- NYU Langone Hospitals New York, NY 90 Hematology & Oncology at NYU Langone Hospitals
- Massachusetts General Hospital Boston, MA 87 Hematology & Oncology at Massachusetts General Hospital
- University of Washington Medical Ctr Seattle, WA 86 Hematology & Oncology at University of Washington Medical Ctr
- Uci Health-Orange Orange, CA 77 Hematology & Oncology at Uci Health-Orange
Clinicians who list the hospital in Medicare Care Compare. The number opens the list of who works there.
Schools they graduated from most
- Jefferson Medical College of Thomas Jefferson University 74
- Wayne State University School of Medicine 72
- Indiana University School of Medicine 70
- New York Medical College 69
- University of Illinois College of Med (chi/peor/rock/chm-Urb) 68
- Albert Einstein College of Medicine of Yeshiva University 66
- Baylor College of Medicine 64
- Temple University School of Medicine 64
- University of Miami, Lm Miller School of Medicine 58
- Ohio State University College of Medicine 57
From Medicare Care Compare (Medicare-enrolled clinicians only).
Industry payments
Drug and device makers reported $64.0M in general payments to 8,631 clinicians in Hematology & Oncology in 2025. See who received the most
Source: CMS Open Payments, program year 2025. A payment is not evidence of wrongdoing.
Research in this field
U.S. researchers published 53,546 articles and reviews in oncology in 2024–2026.
Journals with the most U.S. papers
- Journal of Clinical Oncology Lippincott Williams & Wilkins 2,249
- Cancers Multidisciplinary Digital Publishing Institute 1,010
- Annals of Oncology Elsevier BV 978
- Cureus Cureus, Inc. 902
- Annals of Surgical Oncology Springer Science+Business Media 863
- Gynecologic Oncology Elsevier BV 737
- International Journal of Radiation Oncology*Biology*Physics Elsevier BV 673
- Laboratory Investigation Elsevier BV 652
- Neuro-Oncology Oxford University Press 615
- Transplantation and Cellular Therapy Elsevier BV 615
Most-cited recent papers
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 30,549 times · free to read
- Cancer statistics, 2024 (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 10,142 times · free to read
- Cancer statistics, 2025 (opens in a new tab) CA A Cancer Journal for Clinicians, 2025 · cited 3,609 times · free to read
- Global patterns and trends in breast cancer incidence and mortality across 185 countries (opens in a new tab) Nature Medicine, 2025 · cited 1,408 times
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study (opens in a new tab) The Lancet, 2024 · cited 974 times
- Breast cancer statistics 2024 (opens in a new tab) CA A Cancer Journal for Clinicians, 2024 · cited 905 times · free to read
- The Lancet Commission on prostate cancer: planning for the surge in cases (opens in a new tab) The Lancet, 2024 · cited 827 times · free to read
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (opens in a new tab) New England Journal of Medicine, 2024 · cited 683 times · free to read
From OpenAlex, an open index of research papers. Papers with at least one author at a U.S. institution, classified by subject; the subject covers the whole field, so related specialties share these lists. Citation counts change daily.
Sources: CMS NPPES (counts, sex, credentials), Medicare Care Compare (schools, graduation years, hospitals, telehealth), CMS Medicare Physician & Other Practitioners (2023) and Part D Prescribers (2024), CMS Open Payments (2025), ACGME program requirements (training length), OpenAlex (research), U.S. Census Bureau ACS 2020–2024 (population).